(Q45164423)

English

Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration

scientific article published in December 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

Hepatitis B virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Dai MS

1

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Wu PF

2

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Shyu RY

3

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Lu JJ

4

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Chao TY

5

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

publication date

1 December 2004

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Liver International

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

540-546

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

Efficacy of lamivudine in HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

Molecular Epidemiology of Hepatitis B Viral Serotypes and Genotypes in Taiwan

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

Nucleoside analogues in the treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0964.X

21 January 2018

Identifiers

10.1111/J.1478-3231.2004.0964.X

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45164423&oldid=2068760898"